China Universal Asset Management Co. Ltd. Boosts Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

China Universal Asset Management Co. Ltd. raised its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 10.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,099 shares of the company’s stock after buying an additional 1,732 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Syndax Pharmaceuticals were worth $239,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Syndax Pharmaceuticals in the second quarter valued at $27,000. Values First Advisors Inc. purchased a new position in shares of Syndax Pharmaceuticals in the 3rd quarter worth $30,000. R Squared Ltd bought a new stake in shares of Syndax Pharmaceuticals in the 4th quarter worth about $26,000. Quantbot Technologies LP purchased a new stake in shares of Syndax Pharmaceuticals during the 3rd quarter valued at about $49,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Syndax Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock valued at $58,000 after acquiring an additional 541 shares during the last quarter.

Syndax Pharmaceuticals Price Performance

Shares of SNDX opened at $14.17 on Monday. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -3.90 and a beta of 0.89. Syndax Pharmaceuticals, Inc. has a 1-year low of $12.06 and a 1-year high of $25.34. The company has a 50-day moving average of $14.23 and a 200 day moving average of $17.70.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.15. The firm had revenue of $12.50 million during the quarter, compared to analysts’ expectations of $9.16 million. During the same quarter in the previous year, the firm posted ($0.73) EPS. On average, equities analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.71 earnings per share for the current fiscal year.

Analyst Ratings Changes

SNDX has been the topic of several analyst reports. UBS Group started coverage on Syndax Pharmaceuticals in a research note on Thursday, October 24th. They set a “buy” rating and a $37.00 price objective on the stock. JPMorgan Chase & Co. increased their price target on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a report on Thursday, November 21st. HC Wainwright reaffirmed a “buy” rating and set a $51.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, December 10th. The Goldman Sachs Group increased their target price on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, StockNews.com cut shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 23rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Syndax Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $36.20.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).